oasis 1 oral semaglutide 50 mg nejm 2023 obesity taken once per day in adults with overweight or (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial Daily Oral GLP-1 Receptor Agonist

The brain is not like skin or bone

Understanding these differences helps you make an informed choice about your weight-loss treatment

Rob Berberian , a Newport Beachbased physician specializing in hair restoration and regenerative aesthetic medicine, treats patients from all over Southern California and across the United States for GLP-1related hair thinning

This article summarizes key neuroendocrine and neural circuit mechanisms underpinning current and emerging anti-obesity therapies

Combining treatments should only be done as part of a medically supervised plan

Instead, it targets the central nervous system directly, activating melanocortin receptors in the brain to drive sexual desire at its source